Archive for the ‘CellCyte Genetics Corp. CCYG’ Category

RedChip Featured Company: CellCyte Genetics Corp. (CCYG.OB)

Saturday, August 16th, 2008

Particularly in medicine, the market process is one that takes its cues from no man or government. People and governments may work to influence the markets but capital will always flow to places where it will most likely multiply fastest. Stem cells – and associated therapies/equipment/processes -are one such market. Research and application testing are progressing at such a rapid pace that this new market is inevitable, regardless of moral or political position. An investor can become involved or not, but profit is going to be made and capital will flow as it does.

CellCyte Genetics Corp., a development stage biotechnology company, works to develop and market stem cell therapeutic products and medical devises. The company is currently in the pre-clinical phase of approvals for its stem cell therapy products and clinical trials where its medical tumor identification products are concerned. Acceptable financing has been secured for the company’s clinical and pre-clinical work.

The inevitable reality of stem cell research is a positive one for all companies working within the stem cell field. CellCyte Corp. is one company within the market working to take advantage of the estimated $2 billion stem cell heart segment of the market. There are many areas of research within the stem cell market with CellCyte Corp. choosing to address the particularly critical aspect of stem cell retention within the identified organ. Currently, a high number of stem cells leave the identified organ and are passed out of the body through the liver and spleen. The company’s pre-clinical therapy products aid in the direction of stem cells (or direct injection into the organ) to identified organs while increasing the number that remain in that organ. All apparent indications, at this point, indicate remarkable successes by using umbilical cord or bone marrow stem cells from acceptable donors.

Although the company has a glycoprotein product which may increase speed to trials of its stem cell products, its medical devise division is quite a bit closer to market with several of its stem cell growth and tumor detection devises. With research licensed from the Department of Veterans Affairs, the company’s CCG – T55 diagnostic program can identify tumors (ovarian, breast, prostate and colon) in the very early stages of development. Current processes are only capable of identification to the 5 mm level making the company’s process quite a bit more effective in early tumor detection. As with all of the company’s device products, successes are measured in terms of increasing efficiencies or stem cell cultivation.

The reality of stem cell use is very apparent regardless of how certain policies have worked to slow their development. Progress and breakthroughs have simply outpaced conservative thinking on the subject. Although certain segments of the world have striven to deter this development, most have not; understanding the significance of the overall processes stem cells offer. As successes continue, the market for these processes could begin to rise at an almost parabolic rate. Market growth is estimated to rise from 30%annually in 2012 to over 120% annually in the following years; making an estimated $8 billion market fairly irresistible to even the most skeptical.

Let us hear your thoughts: CellCyte Genetics Corp. Message Board

CellCyte Genetics Corp. (CCYG.OB) Finds Successes in the Realities of Stem Cells and Related Products

Monday, August 11th, 2008

Particularly in medicine, the market process is one that takes its cues from no man or government. People and governments may work to influence the markets but capital will always flow to places where it will most likely multiply fastest. Stem cells – and associated therapies/equipment/processes -are one such market. Research and application testing are progressing at such a rapid pace that this new market is inevitable, regardless of moral or political position. An investor can become involved or not, but profit is going to be made and capital will flow as it does.

CellCyte Genetics Corp., a development stage biotechnology company, works to develop and market stem-cell therapeutic products and medical devices. The company is currently in the preclinical phase of approvals for its stem cell therapy products, and clinical trials where its medical tumor identification products are concerned. Acceptable financing has been secured for the company’s clinical and pre-clinical work.

The inevitable reality of stem cell research is a positive one for all companies working within the stem cell field. CellCyte Corp. is one company within the market working to take advantage of the estimated $2 billion stem-cell heart segment of the market. There are many areas of research within the stem cell market with CellCyte Corp. choosing to address the particularly critical aspect of stem cell retention within the identified organ. Currently, a high number of stem cells leave the identified organ and are passed out of the body through the liver and spleen. The company’s pre-clinical therapy products aid in the direction of stem cells (or direct injection into the organ) to identified organs while increasing the number that remain in that organ. All apparent indications, at this point, indicate remarkable successes by using umbilical cord or bone marrow stem cells from acceptable donors.

Although the company has a glycoprotein product which may increase speed to trials of its stem cell products, its medical device division is quite a bit closer to market with several of its stem cell growth and tumor detection devices. With research licensed from the Department of Veterans Affairs, the company’s CCG – T55 diagnostic program can identify tumors (ovarian, breast, prostate and colon) in the very early stages of development. Current processes are only capable of identification to the 5 mm level, making the company’s process quite a bit more effective in early tumor detection. As with all of the company’s device products, successes are measured in terms of increasing efficiencies or stem cell cultivation.

The reality of stem cell use is very apparent regardless of how certain policies have worked to slow their development. Progress and breakthroughs have simply outpaced conservative thinking on the subject. Although certain segments of the world have striven to deter this development, most have not, understanding the significance of the overall processes stem cells offer. As successes continue, the market for these processes could begin to rise at an almost parabolic rate. Market growth is estimated to rise from 30% annually in 2012 to over 120% annually in the following years, making an estimated $8 billion market fairly irresistible to even the most skeptical.

Let us hear your thoughts below: CellCyte Genetics Corp. Message Board

CellCyte Genetics Corp. (CCYG.OB) Appoints Tony Colasin as Director of Business Development

Friday, November 16th, 2007

CellCyte Genetics Corp. (CCYG.OB) has announced the appointment of Tony Calasin as the company’s Director of Business Development. Tony Calasin will primarily focus on CellCyte’s acquisition and technology licensing, amongst various other tasks.

Tony Colasin, from January 2001 to January 2007, was employed as the Sr. Director of Business Development for ICOS Corporation. During this time period, Tony directed ICOS’ business development during several major product introductions. More notably, Tony Colasin was also responsible for building a urology franchise to leverage the Cialis brand. Cialis is a treatment for erectile dysfunction that, thanks to Colasin’s direction, successfully launched against the primary drug candidate Viagra.

Prior to being employed at ICOS Corporation and Cialis, Mr. Colasin also served as a Sr. Finance Manager for Amgen, Inc. During his period at Amgen, Colasin was responsible for the evaluation of drug candidates and management of such drugs. Furthermore, Colasin was also a Financial Analyst for the $1 billion drug EPOGEN from February 1996 to June 1997. In his early roles with the company, he played a vital part in analyzing forecasts, financial models and sales trends critical to products and markets that the company was pursuing.

Tony Colasin graduated from University of Southern California with a B.S., Business Administration. Shortly thereafter, Colasin received his M.B.A in Finance with an International Business Emphasis from the Anderson School at UCLA.

Let us hear your thoughts below: